ASET study: Long-term follow-up data of patients with metastatic renal cell carcinoma treated with MGN1601.
Viktor Gruenwald(Medizinische Hochschule Hannover), Burghardt Wittig, Manuel Schmidt(Mologen (Germany)), Ahmed Magheli(Johns Hopkins University), Ingo G.H. Schmidt‐Wolf(University Hospital Bonn), Matthias Schroff(Mologen (Germany)), Steffen Weikert(St. Hedwig-Krankenhaus), Stefan Hauser(German Center for Neurodegenerative Diseases)
Cited by 4
Related Papers
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
<i>RUNX1</i>Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
|Journal of Clinical Oncology|2011|450
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
|The Lancet Oncology|2016|218
The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
|European Journal of Cancer|2010|187
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas
|International Journal of Molecular Medicine|2005|151